Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Neurol Neuroimmunol Neuroinflamm 2022;9:e200036. doi:10.1212/NXI.0000000000200036

In the Clinical/Scientific Note “Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod” by Palomares Cabeza et al., the final name in Appendix 2 should be listed as “C.A.C.M. van Els.” The authors regret the error.

REFERENCE